Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Caputo R, Cianniello D, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G.
De Angelis C, et al. Among authors: de placido s, de placido p, de santo i, de laurentiis m.
ESMO Open. 2021 Apr;6(2):100097. doi: 10.1016/j.esmoop.2021.100097.
ESMO Open. 2021.
PMID: 33926709
Free PMC article.
No abstract available.